Hypertrophic Cardiomyopathy—Current Challenges and Future Perspectives.

Recently, an improved comprehension of the underlying causes of HCM has paved the way for the creation of treatments specifically designed to target the underlying substrate, emphasizing the need for an aetiological characterization of patients with HCM [[26]]. Additionally, both obstructive and central sleep apnoea were independently associated with AF, indicating the importance of considering sleep apnoea screening as part of AF management in individuals with HCM [[22]]. In addition, they underscore the critical importance of assembling a multidisciplinary team of HCM experts comprising clinical and interventional cardiologists, along with cardiac surgeons who have substantial expertise in managing patients with obstructive HCM [[32]]. Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by left ventricular (LV) hypertrophy, which cannot be entirely attributed to loading conditions such as valve or congenital heart disease or hypertension [[1]]. [Extracted from the article]